IDEAYA Biosciences (IDYA) Accumulated Expenses (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Accumulated Expenses data on file, last reported at $43.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 32.94% year-over-year to $43.7 million; the trailing twelve-month figure through Mar 2026 stood at $43.7 million (up 32.94% YoY), and the FY2025 full-year result was $11.2 million, down 63.11% from the prior year.
• Accumulated Expenses rose to $43.7 million in Q1 2026, from $11.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $45.3 million in Q3 2025 to a low of $2.6 million in Q1 2022.
• A 5-year average of $17.7 million and a median of $14.7 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses plunged 65.99% in 2022 and jumped 598.17% in 2025, its largest moves.
• Tracing IDYA's Accumulated Expenses over 5 years: stood at $5.2 million in 2022, then soared by 32.89% to $7.0 million in 2023, then soared by 335.22% to $30.4 million in 2024, then slumped by 63.11% to $11.2 million in 2025, then surged by 290.65% to $43.7 million in 2026.
• Business Quant data shows IDYA's Accumulated Expenses at $43.7 million in Q1 2026, $11.2 million in Q4 2025, and $45.3 million in Q3 2025.